Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States

Abstract

We assessed the frequency and severity of adverse events (AEs) in 53 patients with Chagas disease treated with nifurtimox in a US clinic. There were 435 AEs, but 93.8% were mild. Moderate/severe AEs were associated with premature treatment cessation.

State‐of‐the‐art CRISPR/Cas9 Technology for Genome Editing in Trypanosomatids

“…This slow‐progressing, life‐threatening disease affects about 7–8 million people worldwide, mostly in Latin America where the disease is endemic (Forsyth et al. ; Traina et al. ).…”

“…Within trypanosomatids, CRISPR/Cas9 technology was first used to modify the genome of T. cruzi, the causative agent of Chagas disease. This slow-progressing, life-threatening disease affects about 7-8 million people worldwide, mostly in Latin America where the disease is endemic (Forsyth et al 2016;Traina et al 2017). Chagas disease is also the most prevalent parasitic disease in the Americas, with 100 million people at risk and more than 10,000 deaths per year (Montgomery et al 2014).…”

“…Currently, there are only two accepted drugs to treat Chagas disease (Urbina and Docampo 2003). Besides their adverse side effects, the efficacy of these drugs decreases the longer a person has been infected (Forsyth et al 2016). Investigating T. cruzi biology is necessary for the development of alternative therapies to treat the disease.…”

Rescue Therapy with Nifurtimox and Dipyridamole for Severe Acute Chagas Myocarditis with Congestive Heart Failure in NMRI Albino Mice

“…[1][2][3][4] Symptomatic acute ChD cases have been associated with patent parasitemia and severe acute myocarditis, with high morbidity and mortality. 5 Severe heart damage would reflect parasite pathogenic action; therefore, it would be mandatory to conduct aggressive trypanocidal…”

Compostos carbonílicos α,β-insaturados e hidrazonas sintéticas como antiparasitários

“…Frente à tais estatísticas, medidas eficazes de controle e prevenção à doença vem sendo aplicadas, como: a melhoria das habitações para prevenir a infestação do vetor (com paredes de reboco ou concreto); melhorias nas práticas de higiene na preparação, armazenamento, transporte e consumo de alimentos; aplicação de inseticidas ao redor de áreas com alta incidência do vetor; triagem dos doadores de sangue; entre outros. No entanto, a terapêutica atual carece quanto à eficácia e segurança no tratamento dos pacientes, principalmente na fase crônica da doença , (DNDI, 2019;PAHO, 2019a;WHO, 2018b COA et al, 2017;FORSYTH et al, 2016;NUNES et al, 2013;PINAZO et al, 2013;PINHATTI et al, 2016.…”